Philadelphia, PANCT07226232Now EnrollingIRB Ready

Major Depression Clinical Trial in Philadelphia, PA

Access cutting-edge major depression treatment through this phase 3 clinical trial at a research site in Philadelphia. Study-provided care at no cost to qualified participants.

Sponsored by VA Office of Research and Development

Quick Self-Assessment

See if you qualify for this Philadelphia location

Preparing your pre-screening questions…

Expert Care in Philadelphia

Access major depression specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related major depression treatment provided free

Apply for This Philadelphia Location

Check if you qualify for this major depression clinical trial in Philadelphia, PA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Philadelphia

    Convenient for PA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Philadelphia site if eligible
  4. 4Begin participation

About This Major Depression Study in Philadelphia

The purpose of this multi-site randomized controlled trial is to evaluate the efficacy and risks of psilocybin for the treatment of depression in U.S. military Veterans with and without (±) concurrent posttraumatic stress disorder.

Sponsor: VA Office of Research and Development

Who Can Participate

Inclusion Criteria

Veteran of the U.S. military who is English-speaking
Signed informed consent and HIPAA
Adults \</= 75 years of age
Meets DSM-5 criteria for current major depressive episode (MDE)
MADRS \>/= 20 at baseline
Failure to respond satisfactorily to \>/= 2 antidepressant treatments for \>/= 8 weeks, including \>/= 2 weeks at an adequate dose (\>/= 50% of the FDA-approved uppermost dose) for major depression. Augmentation with a medication for depression (e.g., neuroleptics, lithium, levothyroxine) is considered a separate course of treatment.
If applicable, concurrent \& permitted antidepressants must be at stable doses for \>/= 4 weeks prior to baseline (see allowed \& prohibited medication list)
Participants of child-bearing potential must have negative pregnancy test \& agree to adhere to a medically acceptable method of birth control during the study
Has a responsible adult who will provide transportation to the participant's home or place of lodging on the days of psilocybin administration

Exclusion Criteria

Lifetime bipolar, schizophrenia spectrum, or other psychotic disorders
First-degree relative with history of bipolar I, schizophrenia spectrum or other psychotic disorder
Presence of psychotic symptoms (e.g., MDE with psychotic symptoms)
Sedative-hypnotic, stimulant, inhalant and/or opioid use disorder within past 6 months (lifetime substance use disorder is allowed at the discretion of the LSI)
Severe alcohol and/or cannabis use disorder within the past 6 months (mild or moderate alcohol and/or cannabis use is allowed at the discretion of the LSI)
Lifetime hallucinogen persisting perception or hallucinogen use disorders
Use of psilocybin, ayahuasca, mescaline, lysergic acid diethylamide (LSD), dimethyltryptamine (DMT), 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT), peyote, or 3,4-methylenedioxymethamphetamine (MDMA) within past XX months
Participant agrees to not use psychedelics (listed above) during the study, except as prescribed by the study protocol
Taking prohibited medication within 2 weeks of baseline (see allowed and prohibited concomitant medication list)
History of severe traumatic brain injury (TBI)
Diagnosis of dementia or related progressive neurocognitive disorder
Suicidal ideation/behavior Type 4 or Type 5 intensity on C-SSRS within past 6 months of baseline
Psychiatric inpatient treatment within past 3 months of baseline
Treatment with electroconvulsive therapy, deep brain stimulation, vagus nerve stimulation, or transcranial magnetic stimulation within 3 months of baseline
Implanted central nervous system device
Treatment with evidence-based psychotherapy (EBP) for MDD or PTSD within 2 weeks prior to baseline. If receiving EBP therapy, he/she must complete treatment at least 2 weeks prior to baseline. Other forms of non-EBP psychotherapy for MDD or PTSD are allowed to continue during the study period.
Pregnancy or lactation, or anticipated pregnancy or breastfeeding during the active treatment phase
History of myocardial infarction, congestive heart failure, diabetic ketoacidosis, brain cancer, stroke and/or severe cardiac disease
Clinically significant cardiac, pulmonary, renal, liver and/or other medical disease that, in the opinion of the investigator, may contraindicate the use of psilocybin, interfere with the interpretation of study results and/or constitute a health risk for the participant if they take part in the study
Seizure disorder, except for seizures due to fever or withdrawal from a substance
Clinically significant hypertension (\>160/95 mmHg), hypotension (\<90/60 mmHg) tachycardia (\>100 bpm at rest), QTc prolongation (\>450 msec men; \>470 msec women) or clinically significant arrhythmia on ECG
Clinically significant abnormal laboratory results on chemistry panel, liver function tests, complete blood count, and/or thyroid stimulating hormone
Positive urine drug screen for illicit drugs of abuse (except for THC) at screening or baseline
Prior allergic, adverse reaction or adverse experience to a psilocybin formulation
Litigating for disability income for a mental disorder outside the VA compensation and pension process

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Philadelphia?

Yes, this clinical trial (NCT07226232) has an active research site in Philadelphia, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Major Depression Treatment Options in Philadelphia, PA

If you're searching for major depression treatment options in Philadelphia, PA, this clinical trial (NCT07226232) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Philadelphia research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced major depression specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all major depression clinical trials near you to find additional studies recruiting in your area.

More Depression Trials in Philadelphia, PA

See all depression clinical trials recruiting in Philadelphia — not just this study.

Browse Depression Trials in Philadelphia →

Browse More Trials by Condition

Depression TrialsAll Conditions →

Ready to Join in Philadelphia?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Philadelphia, PA